Anti-PD-L1 Monoclonal Antibody

Phase 2Biologic

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Anti-PD-L1 Monoclonal Antibody is one of 55 biologic programs targeting Immune-related Adverse Events. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune-Related Adverse EventsRecruiting

Neoadjuvant ImmunotherapyRecruiting

Non-Small Cell Lung CancerNot yet recruiting

Immune-Related Adverse EventsPhase 2

Recruiting

Neoadjuvant ImmunotherapyPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Zegfrovy

DDizal Pharmaceuticals

Phase 3

5 2

Carboplatin Plus Paclitaxel

Bayer

Phase 3

2 3

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 4

Anti-PD-L1 Monoclonal Antibody

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07288034

Q3 2030

Phase 2Recruiting

Neoadjuvant Immunotherapy

NCT05914389

Q4 2030

Phase 2Recruiting

Immune-Related Adverse Events

NCT06470971

Clinical

Trials by Indication[1]

Immune-related Adverse Events1 trial

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Recruiting·YYuanquan Yang·Phase 2·NCT06470971·40 enrolled

Non-Small Cell Lung Cancer1 trial

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Not yet recruiting·—·Phase 2·NCT07288034·535 enrolled

Neoadjuvant Immunotherapy1 trial

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05914389·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Anti-PD-L1 Monoclonal Antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-PD-L1 Monoclonal Antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-PD-L1 Monoclonal Antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Anti-PD-L1 Monoclonal Antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2030

Q4 2030

Trials by Indication[1]

Immune-related Adverse Events1 trial

Non-Small Cell Lung Cancer1 trial

Neoadjuvant Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News